PATENT CLAIM ANALYSIS

Application Number: 16112195
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-05
Patent Classification: ["424", "722000"]

Abstract:
Described herein is a method for eliminating or reducing ototoxicity in patients receiving a platinum based chemotherapeutic. In particular, are methods of reducing ototoxicity in a pediatric patient. The methods described herein include administering an effective amount of sodium thiosulfate to a patient in need thereof to reduce ototoxicity.

Claim (Index 12):
A dosing regimen for treating a localized and non-metastatic tumor in a pediatric patient of about 18 years of age and under comprising:\n a). administering a dose of about 1 mg/kg to about 5 mg/kg or about 10 mg/m 2  to about 300 mg/m 2  per cycle of cisplatin; b). administering about 5 g/m 2  to about 25 g/m 2  of sodium thiosulfate per cycle of the cisplatin, wherein the sodium thiosulfate is administered from about 2 hours to about 6 hours after the administration of the cisplatin; and wherein the dosing regimen achieves a reduction in ototoxicity when dosed to a pediatric patient compared to a dosing regimen not including the sodium thiosulfate, which is dosed to a pediatric patient, wherein ototoxicity is determined by one or more criteria selected from: a). a reduction in hearing measured by a 20 dB loss at a single frequency; b). a reduction in hearing measured by a 10 dB loss at two consecutive frequencies; c). loss of response at three consecutive test frequencies where responses were previously obtained; d). a reduction in bilateral high-frequency hearing characterized by the criteria:\n i). a <40 dB hearing loss at all frequencies, which indicates a grade 0 or minimal hearing loss; \n ii). a \u226540 dB hearing loss at 8,000 Hz only, which indicates a grade 1 or mild hearing loss; \n iii). a \u226540 dB hearing loss at 4,000 Hz and above, which indicates a grade 2 or moderate hearing loss; \n iv). a \u226540 dB hearing loss at 2,000 Hz and above, which indicates a grade 3 or marked hearing loss; \n v). a \u226540 dB hearing loss at 1,000 Hz and above, which indicates a grade 4 or severe hearing loss; or \n e). a reduction in hearing characterized by the criteria:\n i). a \u226420 dB hearing loss at all frequencies, which indicates a grade 0 hearing loss; \n ii). a >20 dB HL above 4,000 Hz, which indicates a grade 1 hearing loss; \n iii). a >20 dB HL at 4,000 Hz and above, which indicates a grade 2 hearing loss; \n iv). a >20 dB HL at 2,000 Hz or 3,000 Hz, which indicates a grade 3 hearing loss; \n v). a >40 dB HL at 2,000 Hz and above, which indicates a grade 1 hearing loss; \n wherein a change in hearing is computed relative to baseline measures prior to the patient receiving a platinum based chemotherapeutic or sodium thiosulfate or both.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 96.0
- Lexical Diversity: 1.39474
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10694448', '09911195', '11324744', '14989613', '15274529']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7078182820092169
- 35 USC 102 Novelty (BERT): 0.5051017228648862
- Combined Prediction Score: 0.6875466260947838
- Mean Citation Score: 224.011052
- Max Citation Score: 246.93484
- Similarity Product: 160.86831605874295

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test